XTL Biopharmaceuticals Ltd (XTLB) - Cash Flow Conversion Efficiency

Latest as of December 2017: -0.083x

Based on the latest financial reports, XTL Biopharmaceuticals Ltd (XTLB) has a cash flow conversion efficiency ratio of -0.083x as of December 2017. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-301.00K ≈ $-806.97 USD) by net assets (ILA3.62 Million ≈ $9.70K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see XTL Biopharmaceuticals Ltd market cap and net worth for the company's overall valuation and market capitalisation.

XTL Biopharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how XTL Biopharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

XTL Biopharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of XTL Biopharmaceuticals Ltd ranked by their cash flow conversion efficiency. Explore earnings quality score of XTL Biopharmaceuticals Ltd to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
BTU Metals Corp V:BTU	-0.015x
Kingfisher Mining Ltd AU:KFM	-0.073x
Sepatu Bata Tbk JK:BATA	-0.374x
Megaron SA WAR:MEG	0.020x
Pearl Gull Iron Ltd AU:PLG	-0.128x
NCC Group plc LSE:NCC	0.124x
Good Shroom Co Inc V:MUSH	-0.642x
Jain Irrigation Systems Limited NSE:JISLDVREQS	0.032x

Annual Cash Flow Conversion Efficiency for XTL Biopharmaceuticals Ltd (2013–2024)

The table below shows the annual cash flow conversion efficiency of XTL Biopharmaceuticals Ltd from 2013 to 2024. View current stock price of XTL Biopharmaceuticals Ltd for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	ILA5.43 Million ≈ $14.57K	ILA-1.62 Million ≈ $-4.34K	-0.298x	+6.52%
2023-12-31	ILA2.22 Million ≈ $5.95K	ILA-707.00K ≈ $-1.90K	-0.318x	-41.35%
2022-12-31	ILA4.00 Million ≈ $10.72K	ILA-901.00K ≈ $-2.42K	-0.225x	-14.54%
2021-12-31	ILA5.33 Million ≈ $14.30K	ILA-1.05 Million ≈ $-2.81K	-0.197x	-44.61%
2020-12-31	ILA6.25 Million ≈ $16.75K	ILA-850.00K ≈ $-2.28K	-0.136x	-4.56%
2019-12-31	ILA6.98 Million ≈ $18.71K	ILA-908.00K ≈ $-2.43K	-0.130x	-32.67%
2018-12-31	ILA8.32 Million ≈ $22.31K	ILA-816.00K ≈ $-2.19K	-0.098x	+68.46%
2017-12-31	ILA3.62 Million ≈ $9.70K	ILA-1.12 Million ≈ $-3.02K	-0.311x	+51.77%
2016-12-31	ILA2.69 Million ≈ $7.20K	ILA-1.73 Million ≈ $-4.64K	-0.645x	-69.27%
2015-12-31	ILA4.89 Million ≈ $13.10K	ILA-1.86 Million ≈ $-4.99K	-0.381x	+27.86%
2014-12-31	ILA4.68 Million ≈ $12.54K	ILA-2.47 Million ≈ $-6.62K	-0.528x	-43.33%
2013-12-31	ILA6.79 Million ≈ $18.19K	ILA-2.50 Million ≈ $-6.70K	-0.368x	--

About XTL Biopharmaceuticals Ltd

TA:XTLB Israel Biotechnology

Market Cap

$4.49 Million

ILA1.67 Billion ILA

Market Cap Rank

#28880 Global

#418 in Israel

Share Price

ILA1.90

Change (1 day)

+5.56%

52-Week Range

ILA1.60 - ILA8.70

All Time High

ILA14.98